You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oasmia Pharmaceutical's next anti-cancer drug Docecal, has been approved for clinical clients and patient recruitment will commence in January 2016. Docecal is a nanoparticle and water soluble formulation of docetaxel, one of the most commonly used anti-cancer substances in oncology today, in comAlready a subscriber Login You have read all…
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the first child dosed, this Phase 3 trial takes an important step toward establishing dasiglucagon as a potential treatmenAlready a subscriber…
The company announces that the dosing of patients in its first trial PP-CT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is a highly selective and very potent TRPV1 antagonist, previously in development by Bayer Healthcare and XentAlready a subscriber Login You…
The results from the SUSTAIN 7 trial, investigating the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology. The 40-week trial Already a subscriber Login You…
